The packet lists no genes for this condition and records no inheritance pattern or molecular mechanism, so the genetic basis is not characterized here. The disease definition notes that the condition usually occurs after an injury or trauma to the affected limb.

The packet does not contain diagnostic-methods or expert-review diagnosis text, so specific tests or criteria are not certified here. No newborn-screening information is recorded.

Treatment coverage is not certified in this packet. It contains no foundational-therapy records, no expert-review management text and no verified FDA-approved treatment records for this condition, which does not indicate that none exist. The packet does record regulatory designations of several investigational products for this indication, but such designations are not approvals and do not indicate availability.

Prognosis is not certified in this packet, which contains no natural-history text or clinical description from expert review.

According to ClinicalTrials.gov records in the packet, active studies related to this condition are present, including recruiting studies. Listed titles include phase 3 studies of intravenous neridronate in CRPS type 1, a study of conservative treatment, and a transcranial magnetic stimulation study. The packet describes the interventions studied as drug therapy, medical devices, procedural interventions and other interventions, from a mix of industry and academic sponsors, with no gene therapy trials flagged. Its publication digest indicates a literature dominated by reviews and meta-analyses. Active clinical trials for this condition are listed on ClinicalTrials.gov.